pralsetinib (Gavreto) Report issue

Small molecule Orphan Drug FDA Approved FDA Breakthrough Therapy FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1
  • InChIKey: GBLBJPZSROAGMF-RWYJCYHVSA-N
  • Mol. Mass: 533.61
  • ALogP: 4.2
  • ChEMBL Molecule:
    pralsetinib  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$112.4422 - $154.7837
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Organizations (3)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (2)


 

Carcinoma, Medullary

Carcinoma, Non-Small-Cell Lung (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Adenocarcinoma (Phase 3)

Bronchial Diseases (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Bronchogenic (Phase 3)

Carcinoma, Medullary ()

Carcinoma, Non-Small-Cell Lung (Phase 3)

Head and Neck Neoplasms (Phase 3)

Lung Diseases (Phase 3)

Lung Neoplasms (Phase 3)

Neoplasms (Phase 3)

Neoplasms by Histologic Type (Phase 3)

Neoplasms by Site (Phase 3)

Neoplasms, Germ Cell and Embryonal (Phase 3)

Neoplasms, Nerve Tissue (Phase 3)

Respiratory Tract Diseases (Phase 3)

Respiratory Tract Neoplasms (Phase 3)

Small Cell Lung Carcinoma (Phase 3)

Thoracic Neoplasms (Phase 3)

Thyroid Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue